Our Pricing

Mounjaro vs Wegovy UK: Which Weight Loss Injection Is Right for You?

When comparing Mounjaro vs Wegovy UK options, patients often ask which delivers better weight loss results and represents better value. Both are prescription-only GLP-1 receptor agonist injections licensed by the MHRA for chronic weight management, but they work through different mechanisms and show distinct efficacy profiles in clinical trials. This comprehensive comparison examines the clinical evidence, side effects, dosing schedules, and UK pricing to help you make an informed decision with your prescriber.

How Mounjaro vs Wegovy UK Treatments Differ Clinically

The fundamental difference in the Mounjaro vs Wegovy UK comparison lies in their active ingredients and receptor activity. Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist that activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors [1]. Wegovy contains semaglutide, a selective GLP-1 receptor agonist that works through a single pathway [2]. This dual-action mechanism gives Mounjaro a distinct pharmacological profile that may explain differences in weight loss outcomes observed in head-to-head trials.

Both medications slow gastric emptying, reduce appetite, and improve glycaemic control, but tirzepatide's additional GIP receptor activation appears to enhance fat metabolism and insulin sensitivity beyond what semaglutide achieves alone [1]. In clinical practice, this translates to different dosing schedules and titration protocols. Mounjaro starts at 2.5mg weekly and increases to a maximum maintenance dose of 15mg, whilst Wegovy begins at 0.25mg weekly and escalates to 2.4mg over 16-20 weeks [2]. The slower titration with Wegovy aims to minimise gastrointestinal side effects during the adjustment period.

Mounjaro vs Wegovy UK Clinical Trial Results and Weight Loss Data

Direct comparison data from the SURPASS-2 trial, which compared tirzepatide against semaglutide 1mg in type 2 diabetes patients, showed superior weight loss with tirzepatide across all dose levels [3]. Participants on tirzepatide 15mg lost an average of 11.2kg compared to 5.7kg with semaglutide 1mg over 40 weeks. Whilst this trial used a lower semaglutide dose than Wegovy's 2.4mg maintenance dose, it demonstrates tirzepatide's potent weight reduction capacity.

The STEP 1 trial for Wegovy showed participants lost an average of 14.9% of their body weight over 68 weeks on semaglutide 2.4mg [2]. The SURMOUNT-1 trial for Mounjaro demonstrated even greater results, with participants losing up to 22.5% of body weight on the 15mg dose over 72 weeks [1]. When evaluating Mounjaro vs Wegovy UK options, these trial outcomes suggest Mounjaro may deliver approximately 5-8% greater total body weight reduction at maximum doses, though individual responses vary considerably and both medications require ongoing lifestyle modifications for optimal results.

Real-World Effectiveness in UK Patients

Clinical trial data represents controlled conditions, but real-world UK prescribing patterns show both medications deliver meaningful weight loss when combined with dietary changes and increased physical activity. Our clinical team at Cured Pharmacy has supported thousands of patients through weight loss programmes with both treatments. Adherence to the weekly injection schedule and tolerance of gastrointestinal side effects during titration are the primary factors determining long-term success, regardless of which medication is prescribed. Subject to prescriber approval, either option can be appropriate depending on your medical history, previous treatment responses, and cost considerations.

Side Effects: Mounjaro vs Wegovy UK Tolerability Profiles

The side effect profiles for Mounjaro vs Wegovy UK treatments overlap substantially because both medications work through GLP-1 receptor pathways. The most commonly reported adverse effects include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort, particularly during dose escalation phases [1][2]. In the SURMOUNT-1 trial, gastrointestinal events led to treatment discontinuation in approximately 6.2% of tirzepatide participants, whilst STEP trials showed similar discontinuation rates of 4.5-7% for semaglutide [2][3].

Some patients report that Mounjaro's dual-receptor action produces slightly different subjective tolerability, though this varies individually. Both medications carry warnings for potential thyroid C-cell tumours based on rodent studies, and neither should be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1][2]. Pancreatitis risk exists with both treatments, and prescribers carefully screen for contraindications during clinical assessment. When comparing Mounjaro vs Wegovy UK side effect experiences, most patients find the gastrointestinal symptoms manageable and diminishing after the first 4-8 weeks as their body adjusts to the medication.

Managing Side Effects During Treatment

Whether you're prescribed Mounjaro or Wegovy following clinical assessment, practical strategies can minimise side effects. Eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and timing injections consistently help reduce nausea and digestive discomfort. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team provide ongoing support throughout your treatment journey. If side effects become problematic, your prescriber may adjust the titration schedule or consider alternative approaches. Never adjust your dose without consulting your healthcare professional.

Mounjaro vs Wegovy UK Pricing and Value Comparison

Cost represents a significant consideration when evaluating Mounjaro vs Wegovy UK treatment options, as neither medication is currently funded by the NHS for weight management in most clinical commissioning groups. At Cured Pharmacy, Mounjaro is available from £124.99 per month following online clinical assessment, whilst Wegovy starts from £124.99 monthly [4]. The price difference reflects manufacturing costs, market positioning, and dose titration schedules rather than clinical superiority.

When calculating total treatment costs for Mounjaro vs Wegovy UK programmes, consider that both medications typically require 12-18 months of continuous use to achieve and maintain optimal weight loss results. Mounjaro's higher monthly cost may be offset by greater average weight reduction in clinical trials, potentially requiring fewer total months of treatment to reach your goal weight. Conversely, Wegovy's lower starting price makes it more accessible for patients with budget constraints. New patients at Cured Pharmacy can Save £20 off their first order using code Weightlossnew, and we guarantee the lowest UK prices with transparent pricing shown before your consultation begins.

Dosing and Administration: Mounjaro vs Wegovy UK Schedules

Both Mounjaro and Wegovy are administered as once-weekly subcutaneous injections using pre-filled pens, making the practical administration process nearly identical. The key difference in Mounjaro vs Wegovy UK dosing lies in the titration schedule and maximum doses. Mounjaro follows a structured escalation: 2.5mg for 4 weeks, then 5mg, 7.5mg, 10mg, 12.5mg, and finally 15mg if needed, with each increase occurring at 4-week intervals based on tolerability and response [1].

Wegovy's titration extends over a longer period: 0.25mg weekly for 4 weeks, 0.5mg for 4 weeks, 1mg for 4 weeks, 1.7mg for 4 weeks, and finally the maintenance dose of 2.4mg [2]. This more gradual escalation may suit patients particularly concerned about gastrointestinal side effects. Both medications can be injected into the abdomen, thigh, or upper arm, and injection sites should be rotated weekly. When comparing Mounjaro vs Wegovy UK treatment experiences, patients generally find both injection systems straightforward and discreet to use at home after initial training from a healthcare professional.

Injection Technique and Storage Requirements

Proper storage and injection technique ensure optimal efficacy for both treatments. Mounjaro and Wegovy pens must be refrigerated at 2-8°C before first use, though they can be kept at room temperature (below 30°C) for up to 21 days once in use [1][2]. Detailed injection instructions are provided with your medication, and our clinical team at Cured Pharmacy offers guidance during your treatment programme. Both pens are designed for single-patient use only and should never be shared, even if the needle is changed. Subject to prescriber approval and proper training, self-administration is safe and convenient for most patients.

Which Is Better: Mounjaro vs Wegovy UK Prescriber Considerations

The question of which medication is objectively better in the Mounjaro vs Wegovy UK comparison cannot be answered universally, as the optimal choice depends on individual patient factors. Prescribers consider your BMI, weight loss goals, previous medication responses, medical history, budget, and tolerance for potential side effects when recommending treatment. Patients who have previously used liraglutide (Saxenda) with partial success might benefit from escalating to a more potent GLP-1 agonist like Wegovy, whilst those seeking maximum weight reduction and willing to accept higher costs may be suitable candidates for Mounjaro [3].

Clinical assessment through Cured Pharmacy's online consultation process allows UK-registered prescribers to evaluate your eligibility for either medication. Both require a BMI of 30 or above, or 27 or above with weight-related comorbidities such as hypertension or type 2 diabetes. Contraindications including pregnancy, breastfeeding, personal history of medullary thyroid carcinoma, or severe gastrointestinal disease preclude use of both medications [1][2]. The Mounjaro vs Wegovy UK decision ultimately rests with your prescriber's clinical judgement after reviewing your complete medical profile, and both represent evidence-based options for chronic weight management when used alongside lifestyle interventions.

Starting Your Weight Loss Journey at Cured Pharmacy

Whether you proceed with Mounjaro or Wegovy following clinical assessment, Cured Pharmacy provides comprehensive support throughout your treatment. Our UK-registered clinical team (GPhC 9012511) conducts thorough online consultations in under 3 minutes, with prescriptions reviewed by experienced prescribers including superintendent pharmacist Tarun Kumar (GPhC 2233073). We supply only genuine UK-licensed medications with discreet next-day delivery and ongoing clinical support. Transparent pricing means you see the exact cost before your consultation, with no hidden fees. To begin your Mounjaro vs Wegovy UK assessment, complete our confidential online consultation and receive expert guidance on the most appropriate treatment for your weight loss goals.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
2. Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3 trial. The Lancet, 398(10295), 64-77. [accessed 15 August 2026]
4. Cured Pharmacy. (2025). Weight Loss Treatments - UK Online Pharmacy. Retrieved from https://curedpharmacy.com/collections/weight-loss [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.